Dark Forest Capital Management LP Trims Stock Holdings in Enovis Co. (NYSE:ENOV)

Dark Forest Capital Management LP decreased its position in Enovis Co. (NYSE:ENOV - Free Report) by 42.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,997 shares of the company's stock after selling 14,554 shares during the quarter. Dark Forest Capital Management LP's holdings in Enovis were worth $877,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Confluence Investment Management LLC bought a new stake in shares of Enovis in the 4th quarter worth $3,494,000. Geode Capital Management LLC grew its position in Enovis by 9.5% during the third quarter. Geode Capital Management LLC now owns 921,437 shares of the company's stock valued at $39,678,000 after buying an additional 80,165 shares during the period. UMB Bank n.a. increased its holdings in Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after buying an additional 437 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its position in Enovis by 19.5% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 15,433 shares of the company's stock worth $677,000 after acquiring an additional 2,518 shares during the period. Finally, Assenagon Asset Management S.A. purchased a new position in Enovis in the fourth quarter valued at about $437,000. Institutional investors own 98.45% of the company's stock.

Analyst Ratings Changes

Separately, Needham & Company LLC restated a "buy" rating and set a $64.00 price target on shares of Enovis in a research note on Wednesday, April 9th.

Enovis Stock Performance

Shares of NYSE:ENOV traded up $0.52 during mid-day trading on Tuesday, reaching $35.18. The company had a trading volume of 88,627 shares, compared to its average volume of 750,703. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of -16.04 and a beta of 1.86. The company's 50-day moving average price is $36.51 and its 200-day moving average price is $42.00. Enovis Co. has a one year low of $29.32 and a one year high of $56.43.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.06. The company had revenue of $560.98 million for the quarter, compared to analysts' expectations of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. As a group, equities research analysts anticipate that Enovis Co. will post 2.79 EPS for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.